ATE207758T1 - Verwendung von igf-1 - Google Patents

Verwendung von igf-1

Info

Publication number
ATE207758T1
ATE207758T1 AT93910528T AT93910528T ATE207758T1 AT E207758 T1 ATE207758 T1 AT E207758T1 AT 93910528 T AT93910528 T AT 93910528T AT 93910528 T AT93910528 T AT 93910528T AT E207758 T1 ATE207758 T1 AT E207758T1
Authority
AT
Austria
Prior art keywords
pct
igf
treatment
medicament
sec
Prior art date
Application number
AT93910528T
Other languages
English (en)
Inventor
David B Dunger
Martin O Savage
Peter H Soenksen
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE207758T1 publication Critical patent/ATE207758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93910528T 1992-05-19 1993-05-14 Verwendung von igf-1 ATE207758T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1
PCT/SE1993/000425 WO1993023071A1 (en) 1992-05-19 1993-05-14 Use of igf-1

Publications (1)

Publication Number Publication Date
ATE207758T1 true ATE207758T1 (de) 2001-11-15

Family

ID=20386281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910528T ATE207758T1 (de) 1992-05-19 1993-05-14 Verwendung von igf-1

Country Status (11)

Country Link
US (1) US5466670A (de)
EP (1) EP0613376B1 (de)
JP (1) JPH06509361A (de)
AT (1) ATE207758T1 (de)
AU (1) AU669894B2 (de)
CA (1) CA2112358A1 (de)
DE (1) DE69331045T2 (de)
NO (1) NO940180D0 (de)
NZ (1) NZ252359A (de)
SE (1) SE9201573D0 (de)
WO (1) WO1993023071A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US20060088575A1 (en) * 1994-03-31 2006-04-27 Brewitt Barbara A Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ES2208305T3 (es) 1999-04-08 2004-06-16 Genentech, Inc. Composicion basada en polipeptidos de carga opuesta..
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
RU2165767C1 (ru) * 2000-06-09 2001-04-27 Чернов Юрий Николаевич Антидиабетическое средство
JP2004518647A (ja) 2000-12-15 2004-06-24 ナチュラルエンド テック カンパニー リミテッド インシュリン様成長因子−１の分泌誘導用薬剤学的組成物および食品組成物
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
CA2439735A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
JP2008511838A (ja) 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
EP2763692A2 (de) * 2011-10-06 2014-08-13 European Molecular Biology Laboratory Verwendung von igf-1 in der modulation der treg-zellaktivität sowie behandlung und vorbeugung von autoimmunen erkrankungen oder störungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) * 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
SE9201573D0 (sv) 1992-05-19
US5466670A (en) 1995-11-14
AU4098893A (en) 1993-12-13
DE69331045D1 (de) 2001-12-06
NO940180L (no) 1994-01-18
CA2112358A1 (en) 1993-11-25
EP0613376B1 (de) 2001-10-31
EP0613376A1 (de) 1994-09-07
JPH06509361A (ja) 1994-10-20
DE69331045T2 (de) 2002-03-21
AU669894B2 (en) 1996-06-27
WO1993023071A1 (en) 1993-11-25
NZ252359A (en) 1997-05-26
NO940180D0 (no) 1994-01-18

Similar Documents

Publication Publication Date Title
DE69331045D1 (de) Verwendung von igf-1
MX9604635A (es) Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento.
TR200100079T2 (tr) Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
ATE82507T1 (de) Medizinische verwendung.
UA27874C2 (uk) Препарат інсуліну людини, спосіб одержання препарату, спосіб лікування цукрового діабету
ATE150316T1 (de) Verwendung von menschlichem igf-i
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
DE69412486D1 (de) Rekombinante viren und ihre verwendung bei der gentherapie
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE69027217D1 (de) Behandlung von insulinresistentem diabetes
ES2183952T3 (es) Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico.
DE69123361D1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
ATE271880T1 (de) Methoden zur behandlung von diabetes
ATE142500T1 (de) Doppelsträngige rns zur korrektur von abnormalitäten von zirkulierenden immunkomplexen und der monozytenfunktion
ATE104855T1 (de) Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
DE69717301D1 (de) Verwendung von wachstumshormone
DE69227921D1 (de) Herstellung von Proteinen mittels Protein 7B2
CA2116535A1 (en) A Method for Treatment of Patients with Chronic Liver Disease
CA2252560A1 (en) Treatment of partial growth hormone insensitivity syndrome
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.
DE3586321D1 (de) Verwendung von 1,4-dihydropyridinderivaten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties